Text
The EBMT/EHA CAR-T Cell Handbook
Chimeric antigen receptor T cell therapy (CAR-T) is a new class of medicinal products that are genetically engineered from T cells. It is expected that other forms of
Immune Effector Cells-based therapies will soon reach the market, manufactured
from other subsets of immune cells, and engineered through other technologies than
currently used defective retroviral or lentiviral vectors. Cell-based immunotherapies
add to the broader feld of immunotherapies, now populated with monoclonal antibodies including immune checkpoint inhibitors, immune-conjugates, and bi- and
tri-specifc antibodies. Approximately 30 years after the frst publications reporting
on the development of genetically engineered T cells, expression of a frst generation chimeric antigen receptor (CAR), and the demonstration of its capability to
recognize antigens in the absence of MHC presentation in the 1980s, the frst commercially available CAR-T cell medicinal products were approved by the FDA and
later by the EMA for the treatment of relapsed/refractory diffuse large B cell lymphoma and relapsed/refractory acute lymphoblastic leukemia.
No other version available